Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This protocol describes an open-label phase 2 clinical trial of fluoxetine in PAH looking at
change in pulmonary vascular resistance (PVR) as the primary endpoint.
In this open-label clinical trial, 18 patients with pulmonary arterial hypertension will be
given fluoxetine for 24 weeks. A Right Heart Catheterization will be performed at baseline
and 24 weeks. Change in PVR will be the primary endpoint; other hemodynamic endpoints,
quality of life, QIDS-SR depression scale, functional class and six-minute walk distance will
also be evaluated.
Primary Hypothesis: Fluoxetine treatment for 24 weeks will lead to significantly lower
pulmonary vascular resistance in 18 patients with PAH in patients treated in an open-label
clinical trial.